- One-Pot Synthesis of Substituted 2-Amino Isonicotinic Acids: Reminiscent of the Guareschi-Thorpe Condensation
-
This work describes a concise manner to make a wide variety of mono- or disubstituted 2-amino isonicotinic acids via the corresponding 2,4-dioxo-carboxylic acid ethyl esters and ethyl 3-amino-3-iminopropionate hydrochloride. The reaction likely proceeds through an in situ decarboxylation process and is reminiscent of the Guareschi-Thorpe Condensation.
- Deng, Daniel Da,Dong, Weitong,Fu, Yan,Jin, Xiangle,Xing, Lidong,Yan, Jun
-
supporting information
p. 1541 - 1544
(2022/02/07)
-
- A GENERAL PROCESS FOR THE PREPARATION OF 6-SUBSTITUTED OR 5,6-DISUBSTITUTED DERIVATIVES OF 2-AMINO-ISONICOTINIC ACID
-
This invention relates to a novel synthetic method for the preparation of 6-substituted or 5,6-disubstituted derivatives of 2-amino-isonicotinic acid.
- -
-
Page/Page column 9; 10; 25
(2017/01/23)
-
- CO-CRYSTALS AND SALTS OF CCR3-INHIBITORS
-
This invention relates to co-crystals and salts of CCR3 inhibitors of formula (1), pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of diseases related with the CCR3-receptor.
- -
-
Page/Page column 27
(2012/04/23)
-
- CO-CRYSTALS AND SALTS OF CCR3-INHIBITORS
-
This invention relates to co-crystals and salts of CCR3 inhibitors of formula 1, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of diseases related with the CCR3-receptor.
- -
-
Page/Page column 9
(2012/10/23)
-
- SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS
-
Object of the present invention are novel substituted compounds of the formula 1, wherein A, R1, R2, R3 and R4 are defined as in the description. Another object of the present invention is to provide antagonists of CCR3, more particularly to provide pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt thereof.
- -
-
Page/Page column 48
(2010/11/03)
-
